12/10
08:20 am
rlyb
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting [Yahoo! Finance]
Low
Report
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting [Yahoo! Finance]
12/10
08:00 am
rlyb
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
Low
Report
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
12/3
09:03 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
12/2
08:19 am
rlyb
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 [Yahoo! Finance]
Medium
Report
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025 [Yahoo! Finance]
12/2
08:00 am
rlyb
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Medium
Report
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
11/27
08:12 am
rlyb
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women [Yahoo! Finance]
Low
Report
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women [Yahoo! Finance]
11/27
08:00 am
rlyb
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Medium
Report
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
11/26
08:06 am
rlyb
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference [Yahoo! Finance]
Medium
Report
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference [Yahoo! Finance]
11/26
08:00 am
rlyb
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
Low
Report
Rallybio to Present at the 2024 Evercore ISI HealthCONx Conference
11/25
08:22 am
rlyb
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor [Yahoo! Finance]
Low
Report
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor [Yahoo! Finance]
11/25
08:00 am
rlyb
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
Low
Report
Rallybio to Provide Update on RLYB116 Program, an Innovative Subcutaneously Injected C5 Inhibitor
11/22
08:12 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/22
07:38 am
rlyb
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women [Yahoo! Finance]
Medium
Report
Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women [Yahoo! Finance]
11/21
08:27 am
rlyb
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 [Yahoo! Finance]
Low
Report
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212 [Yahoo! Finance]
11/21
08:00 am
rlyb
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
Low
Report
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
11/8
02:32 pm
rlyb
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
Low
Report
Rallybio Co. (NASDAQ: RLYB) had its price target lowered by analysts at HC Wainwright from $6.00 to $5.00. They now have a "buy" rating on the stock.
11/7
08:00 am
rlyb
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
Low
Report
Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
10/30
09:25 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
10/29
08:00 am
rlyb
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
Medium
Report
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
10/24
03:23 pm
rlyb
PhotonPharma Inc. Appoints Derek Brown as New CEO [Yahoo! Finance]
Medium
Report
PhotonPharma Inc. Appoints Derek Brown as New CEO [Yahoo! Finance]
10/1
08:01 am
rlyb
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Rallybio Co. (NASDAQ: RLYB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.